Clarity Pharmaceuticals

Clarity’s Mission

At Clarity, our mission is to develop next-generation radiopharmaceutical products that improve treatment outcomes for people with cancer.

Clarity is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products based on its platform SAR Technology. The SAR Technology is ideally suited for use with copper isotopes, enabling optimal imaging and therapeutic characteristics of radiopharmaceutical products while addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Find out more

Clarity’s clinical development pipeline is underpinned by its proprietary SAR Technology platform that enables highly targeted theranostic radiopharmaceuticals for both the diagnosis (using copper-64) and treatment (using copper-67) of serious diseases.

Clarity’s pipeline covers large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as smaller indications, such as neuroendocrine tumours (NETs).

Clarity’s lead product, SAR-bisPSMA, is in clinical trials for the treatment of prostate cancer as a stand-alone diagnostic as well as a theranostic product. SARTATE is being developed as a diagnostic for NETs. SAR-Bombesin (SAR-BBN) is a pan-cancer product, which is currently being developed for prostate cancer imaging.